Advertisement

Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] Study)

      High residual platelet reactivity (RPR) on clopidogrel treatment has been associated with increased risk for ischemic events during follow-up in patients with acute coronary syndromes. The aim of this study was to assess the incidence, predictors, and clinical consequences of high RPR in a large population of patients with non–ST-segment elevation acute coronary syndromes who underwent percutaneous coronary intervention and stenting. Overall, 833 patients received point-of-care testing of platelet inhibition 30 days after percutaneous coronary intervention. High RPR was diagnosed on the basis of P2Y12 reaction units >230. The incidence and predictors of death, myocardial infarction, stroke, and serious bleeding events were assessed up to 1 year from the day of testing. P2Y12 reaction units were normally distributed, and 264 patients were classified as poor responders (31.7%). Independent predictors of response to clopidogrel were male gender (odds ratio [OR] 1.51), age (OR 0.96), diabetes mellitus (OR 0.51), and use of proton pump inhibitors (OR 0.59). At 1 year, poor responders showed higher rates of death (4.6% vs 1.9%, p = 0.032) and serious bleeding events (4.9% vs 1.8%, p = 0.009) compared with good responders. After adjustment for confounders, high RPR did not emerge as an independent predictor of mortality (OR 0.57, 95% confidence interval [CI] 0.23 to 1.42, p = 0.23) or serious bleeding events (OR 0.61, 95% CI 0.25 to 1.52, p = 0.29). The results did not change using the a cut-off value for P2Y12 reaction units of 208. In conclusion, 1/3 of patients with acute coronary syndromes who underwent percutaneous coronary intervention and stenting showed high on-treatment RPR on bedside monitoring. They had a worse prognosis, but the level of platelet inhibition was not independently associated with the incidence of ischemic or bleeding events.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mehta S.R.
        • Yusuf S.
        • Peters R.J.
        • Bertrand M.E.
        • Lewis B.S.
        • Natarajan M.K.
        • Malmberg K.
        • Rupprecht H.
        • Zhao F.
        • Chrolavicius S.
        • Copland I.
        • Fox K.A.
        Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
        Lancet. 2001; 358: 527-533
        • Angiolillo D.J.
        • Fernandez-Ortiz A.
        • Bernardo E.
        • Alfonso F.
        • Macaya C.
        • Bass T.A.
        • Costa M.A.
        Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.
        J Am Coll Cardiol. 2007; 49: 1505-1516
        • Price M.J.
        • Endemann S.
        • Gollapudi R.R.
        • Valencia R.
        • Stinis C.T.
        • Levisay J.P.
        • Ernst A.
        • Sawhney N.S.
        • Schatz R.A.
        • Teirstein P.S.
        Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
        Eur Heart J. 2008; 29: 992-1000
        • Marcucci R.
        • Gori A.M.
        • Paniccia R.
        • Giusti B.
        • Valente S.
        • Giglioli C.
        • Buonamici P.
        • Antoniucci D.
        • Abbate R.
        • Gensini G.F.
        Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
        Circulation. 2009; 119: 237-242
        • Parodi G.
        • Marcucci R.
        • Valenti R.
        • Gori A.M.
        • Migliorini A.
        • Giusti B.
        • Buonamici P.
        • Gensini G.F.
        • Abbate R.
        • Antoniucci D.
        High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
        JAMA. 2011; 306: 1215-1223
        • Price M.J.
        • Angiolillo D.J.
        • Teirstein P.S.
        • Lillie E.
        • Manoukian S.V.
        • Berger P.B.
        • Tanguay J.F.
        • Cannon C.P.
        • Topol E.J.
        Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
        Circulation. 2011; 124: 1132-1137
        • Brar S.S.
        • ten Berg J.
        • Marcucci R.
        • Price M.J.
        • Valgimigli M.
        • Kim H.S.
        • Patti G.
        • Breet N.J.
        • DiSciascio G.
        • Cuisset T.
        • Dangas G.
        Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
        J Am Coll Cardiol. 2011; 58: 1945-1954
        • Campo G.
        • Parrinello G.
        • Ferraresi P.
        • Lunghi B.
        • Tebaldi M.
        • Miccoli M.
        • Marchesini J.
        • Bernardi F.
        • Ferrari R.
        • Valgimigli M.
        Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.
        J Am Coll Cardiol. 2011; 57: 2474-2483
        • Marzocchi A.
        • Saia F.
        • Piovaccari G.
        • Manari A.
        • Aurier E.
        • Benassi A.
        • Cremonesi A.
        • Percoco G.
        • Varani E.
        • Magnavacchi P.
        • Guastaroba P.
        • Grilli R.
        • Maresta A.
        Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (Registro Angioplastiche dell'Emilia Romagna) multicenter registry.
        Circulation. 2007; 115: 3181-3188
        • Saia F.
        • Piovaccari G.
        • Manari A.
        • Guastaroba P.
        • Vignali L.
        • Varani E.
        • Santarelli A.
        • Benassi A.
        • Liso A.
        • Campo G.
        • Tondi S.
        • Tarantino F.
        • De Palma R.
        • Marzocchi A.
        Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry.
        EuroIntervention. 2009; 5: 57-66
        • Saia F.
        • Piovaccari G.
        • Manari A.
        • Santarelli A.
        • Benassi A.
        • Aurier E.
        • Sangiorgio P.
        • Tarantino F.
        • Geraci G.
        • Vecchi G.
        • Guastaroba P.
        • Grilli R.
        • Marzocchi A.
        Clinical outcomes for sirolimus-eluting stents and polymer-coated paclitaxel-eluting stents in daily practice: results from a large multicenter registry.
        J Am Coll Cardiol. 2006; 48: 1312-1318
        • Trenk D.
        • Hochholzer W.
        • Fromm M.F.
        • Chialda L.E.
        • Pahl A.
        • Valina C.M.
        • Stratz C.
        • Schmiebusch P.
        • Bestehorn H.P.
        • Buttner H.J.
        • Neumann F.J.
        Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
        J Am Coll Cardiol. 2008; 51: 1925-1934
        • Gurbel P.A.
        • Erlinge D.
        • Ohman E.M.
        • Neely B.
        • Neely M.
        • Goodman S.G.
        • Huber K.
        • Chan M.Y.
        • Cornel J.H.
        • Brown E.
        • Zhou C.
        • Jakubowski J.A.
        • White H.D.
        • Fox K.A.
        • Prabhakaran D.
        • Armstrong P.W.
        • Tantry U.S.
        • Roe M.T.
        Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
        JAMA. 2012; 308: 1785-1794
        • Sibbing D.
        • Bernlochner I.
        • Schulz S.
        • Massberg S.
        • Schomig A.
        • Mehilli J.
        • Kastrati A.
        Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
        J Am Coll Cardiol. 2012; 60: 369-377
        • Price M.J.
        • Berger P.B.
        • Teirstein P.S.
        • Tanguay J.F.
        • Angiolillo D.J.
        • Spriggs D.
        • Puri S.
        • Robbins M.
        • Garratt K.N.
        • Bertrand O.F.
        • Stillablower M.E.
        • Aragon J.R.
        • Kandzari D.E.
        • Stinis C.T.
        • Lee M.S.
        • Manoukian S.V.
        • Cannon C.P.
        • Schork N.J.
        • Topol E.J.
        Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
        JAMA. 2011; 305: 1097-1105
        • Collet J.P.
        • Cuisset T.
        • Range G.
        • Cayla G.
        • Elhadad S.
        • Pouillot C.
        • Henry P.
        • Motreff P.
        • Carrie D.
        • Boueri Z.
        • Belle L.
        • Van Belle E.
        • Rousseau H.
        • Aubry P.
        • Monsegu J.
        • Sabouret P.
        • O'Connor S.A.
        • Abtan J.
        • Kerneis M.
        • Saint-Etienne C.
        • Barthelemy O.
        • Beygui F.
        • Silvain J.
        • Vicaut E.
        • Montalescot G.
        Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
        N Engl J Med. 2012; 367: 2100-2109
        • Sibbing D.
        • Schulz S.
        • Braun S.
        • Morath T.
        • Stegherr J.
        • Mehilli J.
        • Schomig A.
        • von Beckerath N.
        • Kastrati A.
        Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
        J Thromb Haemost. 2010; 8: 250-256
        • Jaspers Focks J.
        • Brouwer M.A.
        • van Oijen M.G.
        • Lanas A.
        • Bhatt D.L.
        • Verheugt F.W.
        Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review.
        Heart. 2013; 99: 520-527
        • Gilard M.
        • Arnaud B.
        • Le Gal G.
        • Abgrall J.F.
        • Boschat J.
        Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.
        J Thromb Haemost. 2006; 4: 2508-2509
        • Sibbing D.
        • Morath T.
        • Stegherr J.
        • Braun S.
        • Vogt W.
        • Hadamitzky M.
        • Schomig A.
        • Kastrati A.
        • von Beckerath N.
        Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
        Thromb Haemost. 2009; 101: 714-719
        • Abraham N.S.
        • Hlatky M.A.
        • Antman E.M.
        • Bhatt D.L.
        • Bjorkman D.J.
        • Clark C.B.
        • Furberg C.D.
        • Johnson D.A.
        • Kahi C.J.
        • Laine L.
        • Mahaffey K.W.
        • Quigley E.M.
        • Scheiman J.
        • Sperling L.S.
        • Tomaselli G.F.
        ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
        Circulation. 2010; 122: 2619-2633
        • Cuisset T.
        • Quilici J.
        • Loosveld M.
        • Gaborit B.
        • Grosdidier C.
        • Fourcade L.
        • Gil J.M.
        • Moro P.J.
        • Morange P.E.
        • Bonnet J.L.
        • Alessi M.C.
        Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes.
        Am Heart J. 2012; 164: 327-333
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • Montalescot G.
        • Ruzyllo W.
        • Gottlieb S.
        • Neumann F.J.
        • Ardissino D.
        • De Servi S.
        • Murphy S.A.
        • Riesmeyer J.
        • Weerakkody G.
        • Gibson C.M.
        • Antman E.M.
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • Cannon C.P.
        • Emanuelsson H.
        • Held C.
        • Horrow J.
        • Husted S.
        • James S.
        • Katus H.
        • Mahaffey K.W.
        • Scirica B.M.
        • Skene A.
        • Steg P.G.
        • Storey R.F.
        • Harrington R.A.
        • Freij A.
        • Thorsen M.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057